Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
03 Nov 2023
03 Nov 2023
Historique:
received:
01
06
2023
accepted:
17
10
2023
revised:
04
10
2023
medline:
4
11
2023
pubmed:
4
11
2023
entrez:
4
11
2023
Statut:
aheadofprint
Résumé
Haploidentical stem cell transplantation (Haplo-SCT) using non-myeloablative conditioning regimen (NMAC) has extended the feasibility of allogeneic transplantation, notably in older patients. However, there is few data specifically focusing on patients aged 70 years and over with AML and MDS. Thus the benefit of transplantation in this population is still debated. Here we report our single center experience of peripheral blood Haplo-SCT with NMAC and post-transplantation cyclophosphamide in AML and MDS patients aged 70 years and over. We analyzed 50 patients (27 AML, 23 MDS) with a median age of 72 years (70-77), 12/50 (24%) with active disease at Haplo-SCT. Cumulative incidence of grade 3-4 acute and moderate or severe chronic GVHD were 6% and 25%, respectively. Non-relapse mortality (NRM) at day +100 was 0%. NRM, relapse, PFS and OS at 3 years were 16%, 18%, 66%, and 69%, respectively. Among patients who were disease free at 2 years post Haplo-SCT, 88% are living without immunosuppressive treatment. Peripheral blood Haplo-SCT is feasible in selected AML/MDS patients over 70 years, without any early NRM. It produces long-term disease control and survival. Thus, age by itself should not be considered as a formal barrier to Haplo-SCT.
Identifiants
pubmed: 37923831
doi: 10.1038/s41409-023-02134-w
pii: 10.1038/s41409-023-02134-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Lin RJ, Artz AS. Allogeneic hematopoietic cell transplantation for older patients. Hematol Am Soc Hematol Educ Program. 2021;2021:254–63.
doi: 10.1182/hematology.2021000257
Blaise D, Devillier R, Lecoroller-Sorriano A-G, Boher J-M, Boyer-Chammard A, Tabrizi R, et al. Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. Haematologica. 2015;100:269–74.
pubmed: 25425691
pmcid: 4803127
doi: 10.3324/haematol.2014.113571
Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, et al. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from cancer and leukemia group B 100103 (Alliance for Clinical Trials in Oncology)/blood and marrow transplant clinical trial network 0502. J Clin Oncol. 2015;33:4167–75.
pubmed: 26527780
pmcid: 4658453
doi: 10.1200/JCO.2015.62.7273
Ustun C, Le-Rademacher J, Wang H-L, Othus M, Sun Z, Major B, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019;33:2599–609.
pubmed: 31073153
pmcid: 6842042
doi: 10.1038/s41375-019-0477-x
Versluis J, Hazenberg CLE, Passweg JR, van Putten WLJ, Maertens J, Biemond BJ, et al. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukemia: a time-dependent analysis. Lancet Haematol. 2015;2:e427–36.
pubmed: 26686044
doi: 10.1016/S2352-3026(15)00148-9
Devillier R, Forcade E, Garnier A, Guenounou S, Thepot S, Guillerm G, et al. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Adv. 2022;6:1804–12.
pubmed: 34525180
pmcid: 8941467
doi: 10.1182/bloodadvances.2021004435
Robin M, Porcher R, Adès L, Raffoux E, Michallet M, François S, et al. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome a prospective study on behalf of SFGM-TC and GFM. Leukemia. 2015;29:1496–501.
pubmed: 25676424
doi: 10.1038/leu.2015.37
Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50–75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39:3328–39.
pubmed: 34106753
pmcid: 8791814
doi: 10.1200/JCO.20.03380
Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50.
doi: 10.1016/j.bbmt.2008.03.005
Kasamon YL, Bolaños-Meade J, Prince GT, Tsai H-L, McCurdy SR, Kanakry JA, et al. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol. 2015. https://doi.org/10.1200/JCO.2014.60.4777 .
Imus PH, Tsai H-L, Luznik L, Fuchs EJ, Huff CA, Gladstone DE, et al. Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv. 2019;3:2608–16.
pubmed: 31492679
pmcid: 6737415
doi: 10.1182/bloodadvances.2019000155
Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients Age >69 years with acute myelogenous leukemia: on behalf of the acute leukemia working party of the European society for blood and marrow transplantation. Biol Blood Marrow Transpl. 2019;25:1975–83.
doi: 10.1016/j.bbmt.2019.05.037
Heidenreich S, Ziagkos D, de Wreede LC, van Biezen A, Finke J, Platzbecker U, et al. Allogeneic stem cell transplantation for patients age ≥ 70 years with myelodysplastic syndrome: a retrospective study of the mds subcommittee of the chronic malignancies working party of the EBMT. Biol Blood Marrow Transpl. 2017;23:44–52.
doi: 10.1016/j.bbmt.2016.09.027
McCurdy SR, Kanakry JA, Showel MM, Tsai H-L, Bolaños-Meade J, Rosner GL, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125:3024–31.
pubmed: 25814532
pmcid: 4424420
doi: 10.1182/blood-2015-01-623991
Granata A, Fürst S, Bramanti S, Legrand F, Sarina B, Harbi S, et al. Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients. Bone Marrow Transpl. 2019;54:1730–7.
doi: 10.1038/s41409-019-0500-x
Devillier R, Granata A, Fürst S, Harbi S, Faucher C, Weiller P-J, et al. Low incidence of chronic GVHD after HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in older patients. Br J Haematol. 2017;176:132–5.
pubmed: 27073182
doi: 10.1111/bjh.13923
Duléry R, Goudet C, Mannina D, Bianchessi A, Granata A, Harbi S, et al. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. Bone Marrow Transpl. 2022. https://doi.org/10.1038/s41409-022-01908-y .
doi: 10.1038/s41409-022-01908-y
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl. 2016;22:4–10.
doi: 10.1016/j.bbmt.2015.09.001
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389–401.e1.
doi: 10.1016/j.bbmt.2014.12.001
Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR task force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transpl. 2018;53:1401–15.
doi: 10.1038/s41409-018-0204-7
Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34:541–54.
pubmed: 373811
doi: 10.2307/2530374
Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
doi: 10.1080/01621459.1999.10474144
Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
doi: 10.1080/01621459.1958.10501452
Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3:35–44.
pubmed: 6729287
doi: 10.1002/sim.4780030106
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.
pubmed: 19880497
doi: 10.1182/blood-2009-07-235358
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.
pubmed: 27895058
pmcid: 5291965
doi: 10.1182/blood-2016-08-733196
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–25.
pubmed: 16609072
doi: 10.1182/blood-2005-10-4149
Flannelly C, Tan BE-X, Tan JL, McHugh CM, Sanapala C, Lagu T, et al. Barriers to hematopoietic cell transplantation for adults in the united states: a systematic review with a focus on age. Biol Blood Marrow Transpl. 2020;26:2335–45.
doi: 10.1016/j.bbmt.2020.09.013
Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156–64.
pubmed: 28674027
pmcid: 5580273
doi: 10.1182/blood-2017-03-772368
Imus PH, Blackford AL, Bettinotti M, Luznik L, Fuchs EJ, Huff CA, et al. Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation. Biol Blood Marrow Transpl. 2019;25:2431–7.
doi: 10.1016/j.bbmt.2019.07.027
Devillier R, Bramanti S, Fürst S, Sarina B, El-Cheikh J, Crocchiolo R, et al. T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. Bone Marrow Transpl. 2016;51:194–8.
doi: 10.1038/bmt.2015.270
Robin M, Porcher R, Ciceri F, van Lint MT, Santarone S, Ehninger G, et al. Haploidentical transplant in patients with myelodysplastic syndrome. Blood Adv. 2017;1:1876–83.
pubmed: 29296834
pmcid: 5728144
doi: 10.1182/bloodadvances.2017007146
Al Malki MM, Nathwani N, Yang D, Armenian S, Dadwal S, Salman J, et al. Melphalan-based reduced-intensity conditioning is associated with favorable disease control and acceptable toxicities in patients older than 70 with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2018;24:1828–35.
doi: 10.1016/j.bbmt.2018.04.029
DeZern AE, Elmariah H, Zahurak M, Rosner GL, Gladstone DE, Ali SA, et al. Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-Haploidentical or unrelated peripheral blood grafts and post-transplantation cyclophosphamide. Biol Blood Marrow Transpl. 2020;26:2075–81.
doi: 10.1016/j.bbmt.2020.07.037
Kanakry CG, Bolaños-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, et al. Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood. 2017;129:1389–93.
pubmed: 28049637
pmcid: 5345732
doi: 10.1182/blood-2016-09-737825
Devillier R, Galimard J-E, Labopin M, Blaise D, Raiola AM, Pavlu J, et al. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transpl. 2022;57:1421–7.
doi: 10.1038/s41409-022-01674-x
Legrand F, Le Floch A-C, Granata A, Fürst S, Faucher C, Lemarie C, et al. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. Bone Marrow Transpl. 2017;52:620–1.
doi: 10.1038/bmt.2016.326
Cauchois R, Castagna L, Pagliardini T, Harbi S, Calmels B, Bramanti S, et al. Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells. Br J Haematol. 2019;185:570–3.
pubmed: 30125934
doi: 10.1111/bjh.15544
Bi X, Gergis U, Wagner JL, Carabasi M, Filicko-O’Hara J, O’Hara W, et al. Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies. Bone Marrow Transpl. 2022. https://doi.org/10.1038/s41409-022-01780-w .
Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99:1373–9.
pubmed: 24816237
pmcid: 4116837
doi: 10.3324/haematol.2014.103655
Kennedy VE, Olin RL. Hematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care. Lancet Haematol. 2021;8:e853–61.
pubmed: 34624239
doi: 10.1016/S2352-3026(21)00231-3
Wall SA, Huang Y, Keiter A, Funderburg A, Kloock C, Yuhasz N, et al. Integration of a geriatric assessment with intervention in the care of older adults with hematologic malignancies. Front Oncol. 2021;11:775050.
pubmed: 34956894
pmcid: 8692664
doi: 10.3389/fonc.2021.775050
Sorror ML, Gooley TA, Storer BE, Gerds AT, Sekeres MA, Medeiros BC, et al. An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML. Blood. 2023;141:295–308.
pubmed: 36260765
doi: 10.1182/blood.2022016916